- Your selection
- Clear all
- Pharmaceuticals x
4 case(s) found.
In 2012, GlaxoSmithKline negotiated the largest health-fraud settlement to date with the U.S. Government over allegations of off-label marketing, bribing doctors, and failure to report drug safety problems. As well as the $3 billion settlement, GSK signed a five-year Corporate Integrity Agreement, which included corrective measures in sales and marketing practices.
Reference 6024
Published 29 Jun 2015
Length 6 page(s)
Topic Responsibility
Region Global
Industry Pharmaceuticals
In 2012, GlaxoSmithKline negotiated the largest health-fraud settlement to date with the U.S. Government over allegations of off-label marketing, bribing doctors, and failure to report drug safety problems. As well as the $3 billion settlement, GSK signed a five-year Corporate Integrity Agreement, which included corrective measures in sales and marketing practices.
In October 1988, members of the Board and CEOs of Roussel-Uclaf (one of the French leaders of the pharmaceutical industry) had to decide whether or not to put on the market RU486, a pill that provokes abortion without use of surgical methods.
Reference 2886
Published 01 Jan 1991
Length 16 page(s)
Region Europe
Industry Pharmaceuticals, Medical Practice
In October 1988, members of the Board and CEOs of Roussel-Uclaf (one of the French leaders of the pharmaceutical industry) had to decide whether or not to put on the market RU486, a pill that provokes abortion without use of surgical methods.
Case (B) describes subsequent events: Roussel-Uclaf decides to suspend distribution of the product. However, two days after the firm makes its decision public, the French Government intervenes and mandates the firm to reverse its decision.
Reference 2886
Published 01 Jan 1991
Length 5 page(s)
Region Europe
Industry Pharmaceuticals, Medical Practice
Case (B) describes subsequent events: Roussel-Uclaf decides to suspend distribution of the product. However, two days after the firm makes its decision public, the French Government intervenes and mandates the firm to reverse its decision.
Case (C) describes the French experience with RU486 and the possibilities of making the product available worldwide and emphasises the problems that would arise should it be marketed in the United States, where abortion is a politically sensitive issue, and in the Third World, where the lack of medical facilities would pose a serious risk of the product being misused.
Reference 2886
Published 01 Jan 1991
Length 13 page(s)
Region Europe
Industry Pharmaceuticals, Medical Practice
Case (C) describes the French experience with RU486 and the possibilities of making the product available worldwide and emphasises the problems that would arise should it be marketed in the United States, where abortion is a politically sensitive issue, and in the Third World, where the lack of medical facilities would pose a serious risk of the product being misused.